TGF-beta RI, also called ALK-5, is an approximately 55 kDa type I transmembrane serine/threonine receptor kinase. In the presence of TGF-beta, TGF-beta RI forms a complex with, and is phosphorylated by, TGF-beta RII. Phosphorylated TGF-beta RI can then transiently bind and phosphorylate Smad2 and Smad3. TGF-beta functions as a tumor suppressor by inhibiting the cell cycle in the G1 phase. Administration of TGF-beta is able to protect against mammary tumor development in transgenic mouse models in vivo. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers, with the majority of colon and gastric cancers being caused by an inactivating mutation of TGF-beta RII. TGF-beta RI is likely important during development, since mice deficient for TGF-beta RI die at midgestation with severe defects in vascular development of the yolk sac and placenta, and an absence of circulating red blood cells. Furthermore, TGF-beta RI appears to be involved in proper lymphatic network development.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 μg | 5 days | $ 140.00 | |
50 μg | 5 days | $ 423.00 | |
500 μg | 5 days | $ 2,120.00 | |
1 mg | 5 days | $ 3,170.00 |
Description | TGF-beta RI, also called ALK-5, is an approximately 55 kDa type I transmembrane serine/threonine receptor kinase. In the presence of TGF-beta, TGF-beta RI forms a complex with, and is phosphorylated by, TGF-beta RII. Phosphorylated TGF-beta RI can then transiently bind and phosphorylate Smad2 and Smad3. TGF-beta functions as a tumor suppressor by inhibiting the cell cycle in the G1 phase. Administration of TGF-beta is able to protect against mammary tumor development in transgenic mouse models in vivo. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers, with the majority of colon and gastric cancers being caused by an inactivating mutation of TGF-beta RII. TGF-beta RI is likely important during development, since mice deficient for TGF-beta RI die at midgestation with severe defects in vascular development of the yolk sac and placenta, and an absence of circulating red blood cells. Furthermore, TGF-beta RI appears to be involved in proper lymphatic network development. |
Species | Mouse |
Expression System | Human Cells |
Tag | C-Fc |
Accession Number | Q64729 |
Synonyms | ALK-5, ALK-5ALK5, TGFβRI, tβR-I, LDS1A, TGFbetaRI, TGFB1R1, activin A receptor type II-like kinase, 53kD, TGF-β receptor type I, LDS2A, TGF-bRI, ACVRLK4, TGFR-1, SKR4, TGFBR1, TGF-beta receptor type I, AAT5, tbetaR-I |
Amino Acid | Leu30-Glu125 |
Construction | Recombinant Mouse TGF-beta Receptor Type-1 is produced by our Mammalian expression system and the target gene encoding Leu30-Glu125 is expressed with a human IgG1 Fc tag at the C-terminus. |
Protein Purity | Greater than 95% as determined by reducing SDS-PAGE. (QC verified) |
Molecular Weight | 40-60 KDa, reducing conditions |
Endotoxin | Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test. |
Formulation | Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
Reconstitution | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
Stability & Storage |
Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
Shipping |
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. |
Research Background | TGF-beta RI, also called ALK-5, is an approximately 55 kDa type I transmembrane serine/threonine receptor kinase. In the presence of TGF-beta, TGF-beta RI forms a complex with, and is phosphorylated by, TGF-beta RII. Phosphorylated TGF-beta RI can then transiently bind and phosphorylate Smad2 and Smad3. TGF-beta functions as a tumor suppressor by inhibiting the cell cycle in the G1 phase. Administration of TGF-beta is able to protect against mammary tumor development in transgenic mouse models in vivo. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers, with the majority of colon and gastric cancers being caused by an inactivating mutation of TGF-beta RII. TGF-beta RI is likely important during development, since mice deficient for TGF-beta RI die at midgestation with severe defects in vascular development of the yolk sac and placenta, and an absence of circulating red blood cells. Furthermore, TGF-beta RI appears to be involved in proper lymphatic network development. |
bottom
Please read the User Guide of Recombinant Proteins for more specific information.
TGFBR1 Protein, Mouse, Recombinant (hFc) ALK-5 ALK-5ALK5 TGFβRI ACVRLK 4 tβR-I SKR 4 LDS1A TGFbetaRI TGFB1R1 TGF-b receptor type I ALK5 activin A receptor type II-like kinase, 53kD TGF-β receptor type I ACVRLK-4 LDS2A SKR-4 TGF-bRI AAT 5 TGFBR-1 ACVRLK4 AAT-5 TGFR-1 SKR4 TGFBR1 TGF-beta receptor type I TGFR 1 TGFR1 ALK 5 TGFBR 1 AAT5 tbetaR-I recombinant recombinant-proteins proteins protein